Drug Profile
Research programme: trypanosomiasis therapies - DNDi/Pace University/SCYNEXIS/University of Dundee
Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Drugs for Neglected Diseases Initiative Foundation; Pace University; SCYNEXIS; University of Dundee
- Class Piperidines; Small molecules; Thiazoles
- Mechanism of Action Glycogen synthase kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported African trypanosomiasis
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in African-trypanosomiasis in Switzerland (PO)
- 17 Jul 2014 No development reported - Preclinical for African trypanosomiasis in United Kingdom (PO)
- 17 Jul 2014 No development reported - Preclinical for African trypanosomiasis in USA (PO)